EU funding for CombiGene's epilepsy project is directly relevant for Panion's epilepsy project

Tuesday the 15.th of May, late afternoon, CombiGene's CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene's ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans. During 2017, CombiGene


Click here to see the entire release.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer



Nyemission registrerad hos Bolagsverket

Panion Animal Health AB:s (publ) nyemission är nu delregistrerad hos Bolagsverket


Panion's dog safety study experience a slight delay

Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.


Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018

The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.


Panion in ITF-meeting at EMA


Panion presents for investors at InvestorDagen in Aarhus, DK on the 12.th of June 2018

Panion Animal Health AB is a Swedish registered company with shares on Spotlight/AktieTorget and with a unique product in development - a gene therapy treatment for epilepsy in dogs. We have  a strong Scandinavian cooperation in that half of Panion's management and board resides in Denmark. A safety study in dogs is currently running in Denmark in cooperation with the University of Copenhagen and under the lead of Associate professor David Woldbye, Department of neuroscience, KU.


Slutligt utfall i Panions nyemission

Panion Animal Health AB:s (publ) ("Panion") nyemission av units tecknades till cirka 56 procent och Panion tillförs därigenom en emissionslikvid om cirka 5,2 miljoner kronor före avdrag för emissionskostnader.


Kommuniké från årsstämma i Panion Animal Health AB (publ)

Igår, den 29 maj 2018, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman. 


Board and management members of Panion Animal Health AB (publ), subscribes for shares in the current emission

Panion Animal Health AB ("Panion") is currently offering existing shareholders and others the rights to subscribe for shares in the emission running from 16 - 30 May 2018. The Board of Panion has decided the issue with preference for existing shareholders of a total of approximately SEK 9.2 million.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: